NCT07155759Active, not recruiting
Long-term Outcomes of Prostate Cancer Screening
Long-term Outcomes of Prostate Cancer Screening Using PSA, Biomarkers and MRI: The STHLM3MRI Trial
Source: ClinicalTrials.gov · Last updated 4 Sept 2025
Brief summary (registry, in English)
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 7500 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 1 Nov 2024
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Karolinska Institutet
- Diseases
- Prostate cancer
- NCT number
- NCT07155759
What you commit to
- Study type: Interventional
- Planned participants: 7500
- From 1 Nov 2024 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications for magnetic resonance imaging (MRI) eg pacemaker, magnetic cerebral clips, cochlear implants or severe claustrophobia.
- Men with a previous prostate biopsy the preceding 60 days before invitation.
Other illness
- Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
Who the study is looking for
- Men age 50-74 years without prior diagnosis of prostate cancer (ICD-9 C61).
- Permanent postal address in Stockholm
- Not a previous participant in the Stockholm3 study (2012-2014)
Criteria the registry did not label
- Eligible participants:
- -Men eligible for the longterm f/u-study arms (experimental and control) are participants in the STHLM3MRI trial.
Age in the registry: 50 years to 74 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.